Companies › SIGA Technologies
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Infectious disease; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Smallpox and Mpox Vaccine (JYNNEOS) Live attenuated vaccinia virus vaccine | – | Phase 2 | Smallpox | Jan 2027 |
| Tecovirimat Envelope phospholipase OPG057 inhibitor | – | Phase 2 | Smallpox; Monkeypox | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05597735 | Tecovirimat | Phase 3 | Monkeypox | Infectious disease | Sep 2026 |
| NCT04957485 | Tecovirimat | Phase 2 | Smallpox | Infectious disease | Jan 2027 |
| NCT04957485 | Smallpox and Mpox Vaccine (JYNNEOS) | Phase 2 | Smallpox | Infectious disease | Jan 2027 |
Cash of $116m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Eveliqure Biotechnologies Sanaria Brii Biosciences CastleVax Medicago
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.